HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

IL-2/LAK therapy for refractory acute monoblastic leukemia relapsing after unrelated allogeneic bone marrow transplantation.

Abstract
Leukemia relapse is a major cause of treatment failure after allogeneic bone marrow transplantation. We administered recombinant interleukin-2 (rIL-2) to a patient who relapsed after unrelated allogeneic bone marrow transplantation (uBMT). While the number of peripheral blood monoblastic leukemia cells increased after administration of rIL-2, the patient achieved durable remission for 5 months after low-dose chemotherapy followed by adoptive transfer of engrafted graft-derived lymphokine-activated killer (LAK) cells. Following the disappearance of the blast cells, however, both cutaneous and liver GVHD were exacerbated. Administration of rIL-2 and adoptive transfer of graft-derived LAK cells are considered to be possible choices for the treatment of acute leukemia relapsing after uBMT when donor leukocyte transfusion is not available.
AuthorsH Nagayama, S Takahashi, T Takahashi, K Ogami, K Ikebuchi, A Tojo, K Tani, S Asano
JournalBone marrow transplantation (Bone Marrow Transplant) Vol. 23 Issue 2 Pg. 183-5 (Jan 1999) ISSN: 0268-3369 [Print] England
PMID10197806 (Publication Type: Journal Article)
Chemical References
  • Adjuvants, Immunologic
  • Interleukin-2
  • Peptides
  • poly(lysyl-(leucyl-poly-alanine))
Topics
  • Adjuvants, Immunologic (therapeutic use)
  • Adult
  • Bone Marrow Transplantation
  • Female
  • Humans
  • Interleukin-2 (therapeutic use)
  • Leukemia, Monocytic, Acute (therapy)
  • Peptides (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: